Introduction:
This report provides insight into the management of patients with community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), ventilator-
associated pneumonia (VAP), and health care-associated pneumonia (HCAP) in the hospital setting and analyzes the hospital antibiotic prescribing
practices for the treatment of pneumonia due to emerging and clinically-important pathogens, including MRSA and Pseudomonas aeruginosa.
TreatmentTrends® is a syndicated report series that provides longitudinal information on market dynamics, including insight into practice patterns,
attitudes and perceptions, unmet needs, and projected use of antibiotics in the hospital setting. These studies also explore the perceived advantages
and disadvantages of currently available therapies and therapies in development.
Questions Answered in This Report:
*
Understand how physicians make treatment choices for pneumonia, including choosing empiric treatment
and assessment of patients’ risk for infections due to clinically-important and drug-resistant pathogens
*
Determine which patient subpopulations are difficult-to-treat and identify key areas of need with respect
to pneumonia
*
Understand the pneumonia patient populations treated in the hospital with respect to age, gender,
treatment hospital demographics, risk factors, comorbidities, and treatment outcomes including readmissions
*
Evaluate treatment of the key pathogens (including drug-resistant strains) associated with nosocomial
pneumonia understand which pathogens are of concern to physicians, and which pose new treatment
challenges and drug development opportunities
*
Understand physicians' preference for therapies and analyze factors and drug attributes that influence
their current and future prescribing patterns
*
Understand ID physicians’ receptivity to novel and developing therapies and therapeutic approaches
Scope:
Sample Frame & Methodology:
- Over 100 hospital-based physicians, which
include at least 50 infectious diseases specialists
and 50 critical care/ICU/pulmonary
disease specialists complete a 45-minute
online quantitative survey with several openended
questions for qualitative feedback
- Respondents have at least 50% of their
practice in the hospital, patient-based.
- Minimum of 2 years of post-residency
experience and a maximum of 30 years in
practice
Deliverables:
- Final report in PowerPoint
- Complete set of frequency tables and standard cross tabulations
- Clients committing to the project prior to fielding will be invited to comment on the survey tool and may include up to three proprietary questions in the physician survey
Product Coverage:
PIPERACILLIN-TAZOBACTAM, CARBAPENEMS,
FLUOROQUINOLONES,
TIGECYCLINE, CEFTAZIDIME, CEFEPIME,
CEFTRIAXONE, COLISTIN, AMINOGLYCOSIDES,
CEFTAROLINE, VANCOMYCIN,
LINEZOLID, TELAVANCIN, AND OTHER
SERIOUS GRAM-POSITIVE AGENTS
PHASE II AND III PRODUCTS IN DEVELOPMENT
Related 2012 Products:
- TreatmentTrends®: MRSA and Serious Gram-Positive Infections (EU)
- TreatmentTrends®: Gram-Negative Infections (US)
- TreatmentTrends®: Gram-Negative Infections (EU)
- TreatmentTrends®: MRSA and Serious Gram-Positive Infections (US)
- TreatmentTrends®: MRSA and Serious Gram-Positive Infections (EU)
- LaunchTrends®: Teflaro